Immune histochemical study of apoptosis marker expression and proliferation in tissues at follicular neoplasia of the thyroid gland

Main Article Content

M.Ye. Sazonov
Ye.P. Korchahin
N.I. Goidenko


Background. The purpose was to determine the expression of immune histochemical markers of apoptosis, р53 and bcl-2, and proliferation marker Ki-67 in follicular thyroid neoplasia. Materials and methods. Numerous immune histochemical markers are proposed as criteria for the differential diagnosis of follicular thyroid neoplasia, the most useful of which are Ki-67 proliferation marker and p53 and bcl-2 apoptosis markers. We have conducted immune histochemical study of the surgical material of 50 patients operated in the clinic of State Institution “V. Danilevsky Institute of Endocrine Patho­logy Problems of the NAMS of Ukraine” for benign (25 adenoid tumors) and malignant (25 carcinoma) follicular neoplasms. Results. The obtained data shows that follicular adenomas with solid and fetal-embryonic structure have a high level of correlation with follicular thyroid carcinomas in terms of proliferative activity and dysfunction of apoptosis mechanisms, which, probably, presumes the greatest potential for malignancy and further metastasis. Conclusions. High level of р53 expression and stably high level of bcl-2 expression in the cells of follicle thyroid cancer specifies deep violations of apoptotic processes in development of follicular thyroid neoplasia.

Article Details

How to Cite
Sazonov, M., Y. Korchahin, and N. Goidenko. “Immune Histochemical Study of Apoptosis Marker Expression and Proliferation in Tissues at Follicular Neoplasia of the Thyroid Gland”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 8, Dec. 2017, pp. 541-5, doi:10.22141/2224-0721.13.8.2017.119267.
Clinical Thyroidology


Yassa L, Cibas ES, Benson CB, et al. Longterm assessment of a multidisciplinary approach to thyroid nodulediagnostic evaluation. Cancer. 2007 Dec 25;111(6):508-16. doi: 10.1002/cncr.23116.

Xing М, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013 Mar 23;381(9871):1058-69. doi: 10.1016/S0140-6736(13)60109-9.

Chernukhina DIu, Prilutskii AS. Role of galectin-3, HBME-1 and cytoceratine in immune histochemical diagnostics of papillary thyroid cancer. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2012;5(45):21-23. (in Russian).

Abrosimov AIu, Dvinskikh NY. The diagnostic value of immuno-expression of galectin-3, HBME-1 and cytokeratin-19 in tumors of the thyroid gland of various malignant potentials. Rossiiskii Onkologicheskii Zhurnal. 2010;1:26-31. (in Russian).

Parameswaran R, Brooks S, Sadler GP. Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg. 2010;8(3):186-93. doi: 10.1016/j.ijsu.2010.01.005.

Pujani M, Arora D, Rujani M, Singh SK, Tejwani N. Role of Ki-67 as a proliferative marker in lesions of thyroid. Indian J Cancer. 2010 Jul-Sep;47(3):304-7. doi: 10.4103/0019-509X.64727.

Lacoste-Collin L, d'Aure E, Bérard D, Rouquette I, Delisle MB, Courtade-Saïdi M. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls. Cytopathology. 2014 Jun;25(3):160-9. doi: 10.1111/cyt.12128.

Tsygan VN, Kazakov SP, Zabotina TN, Kushlinskiy NE. Apoptosis and proliferation markers from patients with thyroid oncology and autoimmune diseases. Vestnik rossiiskoi voenno-meditsinskoi akademii. 2010;4(32):197-204. (in Russian).

Khaziev VV, Sorokina IV. Expression of oncomarkers Ki-67 and p53 in thyroid follicular neoplasias. Eksperymental'na i klinichna medycyna. 2013;2(59):77-81. (in Ukrainian).

Berezkina IS, Saprina TV, Zima AP, et al. The problem of molecular diagnostic test value in the differential diagnosis of a thyroid gland nodule. Russian Journal of Biotherapy. 2014;3(13):83-94. (in Russian).

Lehmann BD, Poetenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol. 2012 Oct 10;30(29):3648-50. doi: 10.1200/JCO.2012.44.0412.

Muzhichuk OV, Afanasyeva NI, Muzhichuk VV. Value of the prognostic markers of the tumour progression of P53, P21WAF1/CIP1, P63 and KI-67 in thyroid tumors. The Journal of V. N. Karazin Kharkiv National University, series Medicine. 2009;879(18):4-9. (in Ukrainian).

Bouillet P, Strasser A. Bax and Bak: back-bone of T cell death. Nat Immunol. 2002 Oct;3(10):893-4. doi: 10.1038/ni1002-893.

Avtandilov GG. Osnovy kolichestvennoi patologicheskoi anatomii [Fundamentals of quantitative pathological anatomy]. Мoscow: Meditsina; 2002. 240 p. (in Russian).

Aiad HA, Bashandy MA, Abdou AG, Zahran AA. Significance of AgNORs and ki-67 proliferative mark ers in differential diagnosis of thyroid lesions. Pathol Oncol Res. 2013 Apr;19(2):167-75. doi: 10.1007/s12253-012-9565-1.

Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg. 2010 Dec;34(12):3015-21. doi: 10.1007/s00268-010-0746-3.

Katon R, Suzuki K, Hemmi A, et al. Growth Activity in Hyperplastic and Neoplastic Human Thyroid Determined by an Immunohstochemical Staining Procedure Using Monoclonal Antibody MIB-1. Hum Pathol. 1995 Feb;26(2):139-46. PMID: 7860043.

Koioтecki К, Maciaszczyk P, Stepień H, et al. Evaluation of р53 аnd solubie Fas ligand (sFasL) serum level соnсеntгаtiоn as indicators of apoptosis iп serurn of patients with benign and mаlignаnt primary follicular thyroid tumors. Endokrynol Pol. 2006 Jul-Aug;57(4):320-5. PMID: 17006831.

Hasbek Z, Turgut B, Erselcan T. P53 antibody: is it an indicator of dedifferentiated thyroid cancer? Ann Nucl Med. 2014 Jan;28(1):42-6. doi: 10.1007/s12149-013-0783-8.

Letsas К Р, Fгаngоu-Lаzагidis M, Skyrlas A. Transcription factor-mediated рrolifегаtiоn аnd apoptosis in benign and malignant thyroid lesions. Pathol Int. 2005 Nov;55(11):694-702. doi: 10.1111/j.1440-1827.2005.01899.x.

Thorlacius S, Börresen AL, Eyfjörd JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res. 1993 Apr 1;53(7):1637-41. PMID: 8453635.